Neuronetics® Announces Greenbrook® TMS Installation Milestone for NeuroStar® Advanced Therapy System

Neuronetics® Announces Greenbrook® TMS Installation Milestone for NeuroStar® Advanced Therapy System

MALVERN, PA — Neuronetics, Inc. (NASDAQSTIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, recently announced that Greenbrook TMS, a NeuroStar Advanced Therapy provider with 82 treatment centers across the U.S., has installed its 100th NeuroStar system.

This is a significant milestone in the availability of NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment for patients. Greenbrook’s Matthews, NC location now joins the growing number of practices offering NeuroStar TMS.

As many as 17 million adults in the U.S. live with depression,1 though 5.5 million adults in the U.S. with the disease do not see relief from antidepressant medications2,3,4 — pointing to a significant need for safe and effective non-drug treatment options, such as NeuroStar.

READ:  Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

“TMS is a valuable addition to the treatment of depression,” said Chris Thatcher, President and CEO of Neuronetics. “We remain committed to expanding access to the NeuroStar TMS treatment alongside our valued customers, such as Greenbrook, who share our mission to transform lives and help patients achieve remission from depression with proven and trusted options like NeuroStar. We congratulate Greenbrook TMS on achieving this important milestone in continuing to expand TMS to help patients seek relief from their depression.”

NeuroStar is a non-drug, non-invasive treatment that uses magnetic pulses to stimulate areas of the brain that are underactive in depression.5,6 It offers doctors real-time feedback and delivers enhanced care with its precise and accurate targeting, providing reliable and consistent treatment and making it a best-in-class treatment option. Greenbrook has been treating patients with NeuroStar since 2011.

READ:  Malvern Bancorp, Inc. Not In Compliance with Nasdaq Listing Rule

“Greenbrook TMS is committed to providing life-changing, drug-free treatment for depression. We provide care in communities across the country and strive to equip our doctors with the resources they need to provide the best treatment experience available,” said Bill Leonard, President and CEO of Greenbrook TMS. “We’re proud to have 100 NeuroStar devices installed throughout our centers. Neuronetics is a great partner and we are excited to work together to expand access to safe and effective depression treatment to those in need.”

Since receiving FDA clearance in 2008 as a safe and effective option for adult patients with Major Depressive Disorder (MDD), NeuroStar has been a trailblazer in the depression treatment space and is the number one TMS choice of doctors. In the last decade, more than 2.3 million NeuroStar treatments have been delivered across nearly 800 practice locations in the U.S., and its footprint continues to grow.

READ:  Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Source: Neuronetics, 3222 Phoenixville Pike, Malvern PA 19355

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee